Sagent Pharmaceuticals, a specialty pharmaceutical company focussed on developing, manufacturing, sourcing and marketing pharmaceutical products ,announced the launch of Colistimethate for injection, USP, an anti-infective, in a preservative-free glass vial.

According to IMS, for the 12 months ending October 2014, the US market for Colistimethate approximated $12 million. As with all products in Sagent's portfolio, Colistimethate features Sagent's PreventIV Measures SM packaging and labelling, designed to help reduce medication errors.

Colistimethate for injection, USP is indicated for the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli. It is particularly indicated when the infection is caused by sensitive strains of Pseudomonas aeruginosa.